In these mouse models, progression to carcinomas requires additional genetic and epigenetic changes that intensify MAPK signaling, Wnt pathway activation, and inactivation of cell-cycle and senescence pathways by epigenetic silencing of CDKN2A/p16 [85]. Here, CDKN2A is linked to carcinoma.